Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPI59
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
DPI59 is an experimental small molecule compound classified as a naphthalene derivative, with the chemical formula C11H11O4P and a molecular weight of approximately 238.18 g/mol. It is listed in DrugBank (DB03217) as an experimental agent, but no approved indications or clinical uses are currently reported. The known mechanism of action involves interaction with the proto-oncogene tyrosine-protein kinase Src in humans, though further details on its pharmacodynamics, absorption, metabolism, or toxicity are not available from current sources[1]. No information about its clinical development status or therapeutic area has been published.
- Other names
- DB03217DB-03217DB 03217
02
Targets
SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on DPI59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPI59.